Back to Newsroom

StemCells, Inc. Advances Clinical Trial in Age-Related Macular Degeneration to Final Cohort

Phase I/II AMD Trial on Track to Complete Enrollment in June

NEWARK, Calif., May 22, 2014 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM) announced today that it has transplanted the Company’s proprietary HuCNS-SC® (purified human neural stem cells) into the first five patients in the final cohort of its 16-patient Phase I/II trial for geographic atrophy of age related macular degeneration (GA-AMD). Each of the eight patients in this second cohort will receive a dose of 1 million stem cells into the most affected eye.

Click here to read more